

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/590,445 – Conf. # 6734
				Filing Date	August 24, 2006
				First Named Inventor	Michael Jung
				Art Unit	1614
				Examiner Name	James D. Anderson
Sheet	2	of	7	Attorney Docket Number	58086-235854

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP 362,179	04-04-1990	Smithkline Beecham Corporation		
	B2	WO 00/17163 (with English abstract)	03-30-2000	Yamanouchi Pharmaceutical Co., Ltd., et al.		
	B3	WO 90/13646 (with English abstract)	11-15-1990	Transgene S.A. Achstetter, et al.		
	B4	WO 97/00071	01-03-1997	Biophysica Foundation Sovak, et al.		
	B5	WO 2006/124118	11-23-2006	The Regents of the University of California		
	B6	WO 2005/060661	07-07-2005	The Regents of the University of California		
	B7	WO 2005/059109	06-30-2005	The Regents of the University of California		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Wallen et al., "Androgen Receptor Gene Mutations in Hormone-Refractory Prostate Cancer", J. Pathology 1999, Vol. 189, pages 559-563.	
	C2	Lu et al. "Molecular Mechanisms of Androgen-Independent Growth of Human Prostate Cancer LNCaP-AI Cells", Endocrinology 1999, Vol. 140, No. 11, pages 5054-5059.	
	C3	Karp et al., Cancer Res. 56: 5547-5556.	
	C4	Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).	
	C5	Sambrook et al., Molecular Cloning: A Laboratory Manual 2 nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.	
	C6	Chang et al., Science 240 (4850), 324-326 (1988).	
	C7	NM_000044< gi:21322251">http://www.ncbi.nlm.nih.gov:80/entrez/viewer.fcgi?cmd=Retrieve&db=nucleotide&list_uids=21322251&dopt=GenBank&term=sapiens+AR+androgen+recept+or+prostate+cancer&qty=1>gi:21322251 , printed October 24, 2007.	
	C8	Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991).	
	C9	Graham and van der Eb, Virology, 52:456-467.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--